Cycle Pharmaceuticals, Inc. (Cycle) announces completion of the acquisition of Banner Life Sciences, LLC (Banner) which includes its BAFIERTAM® (monomethyl fumarate) product for the treatment of relapsing forms of multiple sclerosis (MS), in adults, approved by the US Food and Drug Administration (FDA). BAFIERTAM will become Cycle’s second branded product for the treatment of MS alongside TASCENSO ODT® (fingolimod). As with TASCENSO, BAFIERTAM patients will benefit from Cycle’s industry leading hub program, Cycle Vita™*. BAFIERTAM patients will continue to be supported by Banner’s established network during a transition period.
Read the full article: Cycle Pharma Acquires Banner Life Sciences, LLC //
Source: https://www.businesswire.com/news/home/20250113852731/en/Cycle-Pharma-Acquires-Banner-Life-Sciences-LLC